Ventyx Biosciences, Inc. Shareholders Approve Merger with Eli Lilly and Company

Key Event: On March 3, 2026, Ventyx Biosciences, Inc. (Nasdaq: VTYX) announced that its shareholders have overwhelmingly approved the company’s proposed merger with Eli Lilly and Company. This marks a significant milestone in the planned acquisition of Ventyx, which will become a wholly owned subsidiary of Eli Lilly.

Details of the Merger Agreement

• Merger Announcement: Ventyx entered into an Agreement and Plan of Merger with Eli Lilly and Company and RYLS Merger Corporation (a subsidiary of Lilly) dated January 7, 2026.
• Transaction Structure: Under the terms of the merger, RYLS Merger Corporation will be merged with and into Ventyx, with Ventyx surviving as a wholly owned subsidiary of Eli Lilly.

Shareholder Approval and Voting Results

• Special Meeting: A special meeting of Ventyx shareholders was held virtually on March 3, 2026, to vote on the merger and related matters.
• Record Date and Voting Power: As of January 21, 2026, the record date, there were 71,770,778 shares of common stock outstanding, each entitled to one vote per share. A total of 45,810,746 shares were represented in person or by proxy at the meeting.
• Proposal 1 – Approval of Merger Agreement:
  • Votes For: 44,176,785
  • Votes Against: 1,572,592
  • Abstentions: 61,369
  • Broker Non-Votes: 0
  • Result: Approved by an overwhelming majority
• Proposal 2 – Advisory Vote on Executive Compensation (“Golden Parachute” Compensation):
  • Votes For: 43,789,693
  • Votes Against: 1,838,898
  • Abstentions: 182,155
  • Broker Non-Votes: 0
  • Result: Approved
• Proposal 3 – Adjournment of the Special Meeting: This proposal was rendered moot and not presented, as the merger agreement was already approved.

What Shareholders Need to Know

• Completion of the Transaction: The approval of the merger by shareholders clears a major hurdle for the acquisition to close. The merger will result in Ventyx becoming a wholly owned subsidiary of Eli Lilly, which may lead to a delisting of Ventyx shares from the Nasdaq Global Select Market.
• Consideration for Shareholders: Although the document does not specify the per-share merger consideration, such transactions typically involve a cash or stock payment to Ventyx shareholders. Investors should review the previously distributed proxy statement for exact financial terms.
• Executive Compensation: Shareholders approved, on a non-binding basis, the compensation arrangements (“golden parachutes”) for named executive officers in connection with the merger. This is important as such compensation agreements can be material in the context of an acquisition.
• Regulatory and Other Approvals: The merger remains subject to customary closing conditions, including regulatory approvals. Any failure to obtain such approvals could impact the timing or completion of the deal.

Potential Impact on Share Price

• Price Sensitivity: The approval of the merger is a significant, price-sensitive event. It typically sets a floor for the stock price near the agreed acquisition price (if higher than the prevailing market price), but it also means Ventyx will likely cease trading as an independent company upon closing.
• Arbitrage Opportunity: Investors may now trade Ventyx shares based on the spread between the current market price and the expected merger consideration, adjusted for any perceived risks of deal completion.

Other Relevant Information

• NASDAQ Listing: Ventyx’s common stock is currently traded under the symbol VTYX on the Nasdaq Global Select Market.
• Emerging Growth Company: Ventyx does not qualify as an emerging growth company under SEC rules.
• Next Steps: Investors should monitor for further announcements regarding the closing of the transaction and any instructions for exchanging shares for merger consideration.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to sell or the solicitation of an offer to buy any securities. Shareholders are encouraged to read all official SEC filings and consult with their financial advisors regarding the implications of the merger.

View Ventyx Biosciences, Inc. Historical chart here